Absci Co. (NASDAQ:ABSI - Get Free Report) shares gapped up before the market opened on Tuesday . The stock had previously closed at $5.82, but opened at $6.27. Absci shares last traded at $6.29, with a volume of 3,597,708 shares trading hands.
Wall Street Analysts Forecast Growth
ABSI has been the topic of several recent analyst reports. HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Absci in a research note on Friday, January 17th. Needham & Company LLC assumed coverage on Absci in a research note on Wednesday, January 22nd. They set a "buy" rating and a $9.00 target price on the stock. KeyCorp lowered their price target on Absci from $6.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Finally, Guggenheim reissued a "buy" rating and set a $10.00 price target on shares of Absci in a report on Tuesday, December 3rd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Absci currently has an average rating of "Buy" and an average price target of $8.57.
Check Out Our Latest Research Report on ABSI
Absci Price Performance
The firm has a fifty day moving average price of $3.74 and a two-hundred day moving average price of $3.77. The stock has a market capitalization of $513.42 million, a P/E ratio of -4.81 and a beta of 2.11. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63.
Hedge Funds Weigh In On Absci
A number of institutional investors have recently bought and sold shares of ABSI. PCA Investment Advisory Services Inc. bought a new position in Absci in the 4th quarter worth $26,000. Alpha Cubed Investments LLC bought a new position in Absci in the 4th quarter worth $26,000. Ballentine Partners LLC bought a new position in Absci in the 4th quarter worth $27,000. BNP Paribas Financial Markets bought a new position in Absci in the 4th quarter worth $28,000. Finally, Verdence Capital Advisors LLC bought a new position in Absci in the 4th quarter worth $37,000. 52.05% of the stock is owned by institutional investors.
Absci Company Profile
(
Get Free Report)
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
Recommended Stories
Before you consider Absci, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Absci wasn't on the list.
While Absci currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
